纠正METTL4介导的线粒体DNA 6mA过量可缓解心力衰竭
该研究通过血管紧张素II/苯肾上腺素灌注或心肌缺血再灌注建立心衰模型,发现衰竭心肌细胞线粒体DNA(mtDNA)的N6-甲基腺嘌呤(6mA)及甲基转移酶METTL4升高,METTL4通过干扰mtDNA转录起始导致线粒体功能障碍。心肌细胞特异性敲除Mettl4或沉默METTL4可恢复线粒体功能并减轻心衰。
要点
- 心衰心肌细胞mtDNA 6mA和METTL4表达升高,靶向抑制METTL4可改善线粒体功能。
- METTL4通过优先甲基化mtDNA启动子区域干扰转录起始复合物组装。
- p53是应激条件下调控METTL4转录的直接因子,介导mtDNA 6mA升高。
核心结论
- 心肌细胞mtDNA 6mA及其甲基转移酶METTL4在心力衰竭的线粒体功能障碍和发病中起关键作用。
- 靶向抑制METTL4以纠正mtDNA 6mA过量是开发线粒体聚焦心衰干预的有前景策略。
研究设计与样本
- 实验性心衰模型通过持续输注血管紧张素II和苯肾上腺素或延长心肌缺血/再灌注损伤建立。
- 使用高分辨率质谱和甲基化DNA免疫沉淀测序表征衰竭心肌细胞mtDNA的6mA甲基化图谱。
- 采用他莫昔芬诱导的心肌细胞特异性Mettl4敲除小鼠模型和腺相关病毒载体靶向调控METTL4表达。
主要发现
- METTL4主要定位于成年心肌细胞线粒体,mtDNA中6mA修饰显著多于核DNA。
- 出生后心肌细胞成熟伴随mtDNA 6mA水平和METTL4表达降低,而衰竭成年心肌细胞中两者均升高。
- METTL4优先靶向mtDNA启动子区域,干扰转录起始复合物组装,导致mtDNA转录停滞和线粒体功能障碍。
- 通过METTL4过表达扩增心肌细胞mtDNA 6mA可导致自发性线粒体功能障碍和心衰表型。
- p53被鉴定为响应心衰诱发应激的METTL4转录直接调控因子。
关键数值与推荐
- 心肌细胞特异性删除Mettl4基因可消除mtDNA 6mA过量,保留线粒体功能,并减轻持续输注AngII/PE后的心衰发展。
- 在已有心衰的小鼠中,心肌细胞特异性沉默METTL4可恢复线粒体功能并提供治疗缓解,无论心衰由AngII/PE输注还是心肌缺血/再灌注损伤诱导。
临床怎么用
- 靶向抑制METTL4以纠正mtDNA 6mA过量可能成为线粒体聚焦的心衰治疗策略。
- METTL4和mtDNA 6mA可作为心衰线粒体功能障碍的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial mitochondrial dysfunction underpins the pathogenesis of heart failure (HF), yet therapeutic options to restore myocardial mitochondrial function are scarce. Epigenetic modifications of mitochondrial DNA (mtDNA), such as methylation, play a pivotal role in modulating mitochondrial homeostasis. However, their involvement in HF remains unclear. METHODS: Experimental HF models were established through continuous angiotensin II and phenylephrine (AngII/PE) infusion or prolonged myocardial ischemia/reperfusion injury. The landscape of N6-methyladenine (6mA) methylation within failing cardiomyocyte mtDNA was characterized using high-resolution mass spectrometry and methylated DNA immunoprecipitation sequencing. A tamoxifen-inducible cardiomyocyte-specific Mettl4 knockout mouse model and adeno-associated virus vectors designed for cardiomyocyte-targeted manipulation of METTL4 (methyltransferase-like protein 4) expression were used to ascertain the role of mtDNA 6mA and its methyltransferase METTL4 in HF. RESULTS: METTL4 was predominantly localized within adult cardiomyocyte mitochondria. 6mA modifications were significantly more abundant in mtDNA than in nuclear DNA. Postnatal cardiomyocyte maturation presented with a reduction in 6mA levels within mtDNA, coinciding with a decrease in METTL4 expression. However, an increase in both mtDNA 6mA level and METTL4 expression was observed in failing adult cardiomyocytes, suggesting a shift toward a neonatal-like state. METTL4 preferentially targeted mtDNA promoter regions, which resulted in interference with transcription initiation complex assembly, mtDNA transcriptional stalling, and ultimately mitochondrial dysfunction. Amplifying cardiomyocyte mtDNA 6mA through METTL4 overexpression led to spontaneous mitochondrial dysfunction and HF phenotypes. The transcription factor p53 was identified as a direct regulator of METTL4 transcription in response to HF-provoking stress, thereby revealing a stress-responsive mechanism that controls METTL4 expression and mtDNA 6mA. Cardiomyocyte-specific deletion of the Mettl4 gene eliminated mtDNA 6mA excess, preserved mitochondrial function, and mitigated the development of HF upon continuous infusion of AngII/PE. In addition, specific silencing of METTL4 in cardiomyocytes restored mitochondrial function and offered therapeutic relief in mice with preexisting HF, irrespective of whether the condition was induced by AngII/PE infusion or myocardial ischemia/reperfusion injury. CONCLUSIONS: Our findings identify a pivotal role of cardiomyocyte mtDNA 6mA and the corresponding methyltransferase, METTL4, in the pathogenesis of mitochondrial dysfunction and HF. Targeted suppression of METTL4 to rectify mtDNA 6mA excess emerges as a promising strategy for developing mitochondria-focused HF interventions.
引用
- Zhang, Zhang, Hu, et al. Rectifying METTL4-Mediated N6-Methyladenine Excess in Mitochondrial DNA Alleviates Heart Failure. Circulation. 2024. PMID: 38686562. doi:10.1161/CIRCULATIONAHA.123.068358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。